Clinical Trial

Platino-resistance in Ovarian Cancer

Study acronym: PlatinOv
Recruiting
View on ClinicalTrials.gov →
Summary
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. A prospective database and an associated biological collection will be performed during 5 years: * For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study). Study participation of each patient will be 5 years.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-05-15; most recent amendment 2025-11-14.
Status change: Suspended → Recruiting 2020-05-07
Status change: Recruiting → Suspended 2020-04-01
Status change: Not Yet Recruiting → Recruiting 2020-01-27
Trial Details
NCT Number NCT03954171
Lead Sponsor Institut Claudius Regaud
Conditions Epithelial Ovarian Cancer
Enrollment 600 participants
Start Date 2020-03-06
Primary Completion 2033-03 (estimated)
Study Completion 2033-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-18